At present, there are many clinical trials of chemotherapy drugs combined with anti-PD-1 antibody in the treatment of tumor, but the clinical study of CAV / IE chemotherapy combined with anti-PD-1 antibody in the treatment of advanced or non resectable bone and soft tissue sarcoma has not been started, and the related research is still in the blank state. In view of the above problems, to observe and evaluate the efficacy and safety of CAV / IE chemotherapy combined with toripalimab in the treatment of advanced or non resectable bone and soft tissue sarcoma patients, so as to provide more treatment options for patients with advanced or non resectable bone and soft tissue sarcoma.
The aim of this study was to investigate the efficacy and safety of CAV / IE chemotherapy combined with toripalimab in the treatment of patients with advanced or unresectable bone and soft tissue sarcomas who failed in standard treatment.